(Q35612898)

9 August 2017

title

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation (English)

1 reference

9 August 2017

0 references

Martijn P Lolkema

1

1 reference

9 August 2017

Hilde H Bohets

2

1 reference

9 August 2017

Hendrik-Tobias Arkenau

3

1 reference

9 August 2017

Ann Lampo

4

1 reference

9 August 2017

Erio Barale

5

1 reference

9 August 2017

Maja J A de Jonge

6

1 reference

9 August 2017

Leni van Doorn

7

1 reference

9 August 2017

Peter Hellemans

8

1 reference

9 August 2017

Johann S de Bono

9

1 reference

9 August 2017

Ferry A L M Eskens

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

5 March 2015

1 reference

9 August 2017

published in

Clinical Cancer Research

1 reference

9 August 2017

volume

21

1 reference

9 August 2017

issue

10

1 reference

9 August 2017

page(s)

2297-2304

1 reference

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Ron kinase transphosphorylation sustains MET oncogene addiction

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

The Met tyrosine kinase receptor in development and cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Drug-metabolizing ability of molybdenum hydroxylases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Epithelial-mesenchymal transitions in tumour progression

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

A novel germ line juxtamembrane Met mutation in human gastric cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Activating mutations for the met tyrosine kinase receptor in human cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Clinical pharmacokinetics of probenecid

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Inhibitory effects of Ruta graveolens L. extract on guinea pig liver aldehyde oxidase.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Human liver aldehyde oxidase: inhibition by 239 drugs

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4433755

Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25745036

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25745036

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-14-3258

1 reference

9 August 2017

1 reference

9 August 2017

1 reference